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Forty five percent of the Israeli population were infected with the
influenza B Victoria virus during the winter season 2015–16
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ABSTRACT
While infection with influenza A viruses has been extensively investigated,
infections with influenza B viruses which are commonly categorized into the
highly homologous Victoria and Yamagata lineages, are less studied, despite their
considerable virulence. Here we used RT-PCR assays, hemagglutination inhibition
assays and antibody titers to determine the levels of influenza B infection. We report
of high influenza B Victoria virus prevalence in the 2015–16 winter season in Israel,
affecting approximately half of the Israeli population. We further show that the
Victoria B virus infected individuals of all ages and that it was present in the country
throughout the entire winter season. The vaccine however included the inappropriate
Yamagata virus. We propose that a quadrivalent vaccine, that includes both Yamagata
and Victoria lineages, should be considered for future influenza vaccination.

INTRODUCTION

are similar and their hemagglutinin proteins show
approximately 96% homology. New influenza B virus
strains constantly evolve because the segmented viral
genome has allowed the genetic reassortment between
viruses of different lineages during co-infection [12, 13].
The two antigenically and genetically distinct
influenza B viruses, have been circulating in humans since
1983. Between 1992 and 2000, Victoria lineage viruses were
detected only in eastern Asia. From March to September of
2001 and during the 2001–2002 influenza season, Victoria
lineage viruses were detected in several countries for the
first time in a decade [14].
Several studies have demonstrated that influenza
B infections can be quite dominant in a single season
or across consecutive seasons [15, 16]. Yet, despite the
importance of influenza B viruses, much of the published
scientific literature regarding the epidemiology of
influenza focused on influenza A. As a result, the global

Influenza viruses, which are members of the
Orthomyxoviridae family, are categorized into three genera
- A, B, and C [1, 2]. Infections with influenza viruses are
a major cause of morbidity and mortality worldwide [3–
5]. Indeed, approximately 3–5 million individuals suffer
from severe illness each year with an estimated 250,000–
500,000 related deaths [6]. The influenza virus undergoes
rapid and significant changes that prevent the generation
of long-lasting protective immunity [7, 8]. In attempt to
prevent infection, the influenza vaccine composition, is
re-evaluated every year. The trivalent vaccine usually
contains two influenza A and one influenza B virus.
Influenza B viruses can be divided into two distinct
lineages Victoria (denoted B/Victoria/2/87) and Yamagata
(denoted B/Yamagata/16/88) [9–11]. The two lineages
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epidemiology and disease burden of influenza B viruses is
still poorly understood.
The influenza trivalent vaccine given in the 2015–16
season included the A/California/7/2009 (H1N1)-like,
A/Switzerland/9715293/2013 (H3N2)-like and influenza
B/Phuket/3073/2013-like (B/Yamagata lineage) viruses.
Evidence from the southern hemisphere and our
own observations in Israel (manuscript submitted for
publication), indicated that the vaccine given in the 2015–16
season was inefficient, as a significant number of individuals
were infected with the influenza B and with the pandemic
influenza viruses [6, 17].
The purpose of the current study was to characterize
the influenza B infection during the 2015–16 season in
Israel.

were detected in only 5% of the patient samples,
while in the last winter season (2015–16), 50% of the
influenza-infected individuals were due to influenza B
(Figure 1). Interestingly, a single influenza B lineage
dominated in each of the examined winter seasons. In
2011–12 and in 2015–16, the Victoria lineage was
dominant, while in 2012–15, the Yamagata lineage was
responsible for most influenza B infections (Figure 1).
Analysis of the weekly distribution of Yamagata and
Victoria influenza B viruses in the 2015–16 season showed
that these viruses were detectable throughout the winter
season (Figure 2).

RESULTS

To test the extent of exposure to Yamagata and
Victoria viruses in the Israeli population (both symptomatic
and asymptomatic infection), we conducted a seroprevalence study in which we examined sera obtained
in 2014, when Yamagata lineage was most prevalent
(Figure 1) and in 2016, when the Victoria lineage was
most prevalent (Figure 1). No significant differences in
Yamagata virus antibody titers in 2014 versus 2016 were
noted (Figure 3A). In contrast, high antibody titers against
Victoria were observed in 2016 (Figure 3B). These results
prompted us to quantify the percentages of individuals
having anti-Yamagata and anti-Victoria antibodies in
2014 and in 2016. Strikingly, while the percentage
of individuals carrying antibodies against Yamagata
was not significantly different between 2014 and 2016
(Figure 4A), 45% more individuals had anti-Victoria
antibodies in 2016 as compared to 2014 (Figure 4B).

Sero-prevalence of antibodies to Yamagata and
Victoria viruses

Influenza B virus infection prevalence between
2011 and 2016
To examine the prevalence of infection by Yamagata
and Victoria influenza B lineages, we determined their
presence in patient samples collected between 2011 and
2016. Samples were obtained from patients suffering from
Influenza-like illness (ILI), collected from sentinel clinics
throughout Israel. In general, the percentages of patient
samples infected with influenza B viruses varied over the
years and peaks of influenza B infection were observed in
the years following those in which influenza B viruses were
hardly present (Figure 1). In 2011–12 and in 2013–14, 35%
of all influenza infections were due to influenza B viruses. In
contrast, in 2012–13 and in 2014–15, influenza B infections

Figure 1: Prevalence of influenza B infections in Israel between 2011 and 2016. The presence of Yamagata and Victoria
influenza B lineages, in community patients with ILI.
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Figure 2: Weekly distribution of influenza B infection. The graph demonstrates the weekly distribution of influenza B Yamagata
and Victoria lineages detected in community ILI patients in 2015–16.

Figure 3: Prevalence of antibodies against Yamagata and Victoria in 2014 and 2016. Seropositivity against Yamagata (A) and
Victoria (B) in 2014 and in 2016 in serum, samples stored in the Israel National Serum Bank established by the Israel Center for Disease Control.
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This observation indicates that at least 45% of the
population was infected with influenza B Victoria in the last
winter season.
Finally, we analyzed the age distribution of the
influenza-infected individuals. As presented in Figure
5, anti-Yamagata antibodies were detected in all age
groups, in a relatively large percentages of the population
examined in both 2014 and in 2016 (Figure 5A). Although
anti-Victoria antibodies were detected in all age groups in
both seasons, the percentages of individuals expressing
anti-Victoria antibodies was higher in 2016 as compared
to 2014 (Figure 5B).

Victoria virus infections, suggest that the current vaccine
is not effective against the influenza B/Victoria lineage. It
is possible that some individuals infected with influenza
B/Victoria were asymptomatic but were involved in
transmitting the infection as suggested by Hsu et al., [20]
and as observed for asymptomatic children infected with
H1N1 in Taiwan [20, 21].
The level of cross-protection between the two B
lineages is assumed to be low. Few reports have shown
that infection with the Yamagata lineage influenza
B virus may induce cross-lineage antibody response
against the Victoria lineage as well, however, infection
with the Victoria lineage fails to provide adequate
protection [22–24].
Studies in the United States have shown that the
frequent influenza B vaccine mismatches of recent years
have been associated both with substantial increases
in infection, hospitalizations and deaths [25], and with
high influenza-related medical costs [26, 27]. Thus,
considering the findings presented here, we recommend
use of a quadrivalent influenza vaccine that contains the
two influenza B lineages.

DISCUSSION
Accurate determination of the prevalence of specific
lineages of circulating influenza viruses provides public
health officials with information required to evaluate
vaccination programs and allocate resources. The data also
aid in the design of more effective vaccines and can assess
whether immunity against one particular strain is effective
against another influenza virus strain.
Following assessments of the 2000–02 influenza
infection profiles, when the Victoria lineage became
predominant worldwide [14], the World Health
Organization recommended use of strain B/Hong
Kong/330/2001 (Victoria lineage) in the vaccine of
2002–2003 [18, 19]. It was reported that in the southern
hemisphere, some individuals were infected with the
influenza/B Victoria virus. Here, we report that in the
2015–16 winter season, 45% of the Israeli population were
infected with influenza B Victoria virus. In the last winter
season, approximately 1.7 million individuals (20% of
the population), 60.4% whom were above the age of 65,
were vaccinated with the seasonal influenza vaccine in
Israel. Approximately 90% of them received the trivalent
vaccine, and 10% received the quadrivalent vaccine.
These data, along with the reported high prevalence of

MATERIALS AND METHODS
Clinical samples
Nasopharyngeal and serum samples were used for
our evaluation. Nasopharyngeal samples were collected as
part of the community influenza surveillance conducted in
collaboration with the Israel Center for Disease Control
(ICDC). These samples were collected from over 20
outpatient clinics, from 1919 patients presenting with
influenza-like illness (ILI) during the influenza season
spanning between October 2015 and April 2016.
Serum samples (N = 1,018) were obtained from
the Israel National Serum Bank established by the Israel
Center for Disease Control. The samples were collected

Figure 4: Prevalence of antibodies against Yamagata and Victoria in the entire population. Presence of antibodies to
Yamagata (A) and Victoria (B) influenza B viruses in 2014 and in 2016 in serum samples.
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from individuals in 2014 and in 2016. Details regarding
age groups, gender and geographical region of residence
in Israel were available to the researchers and patient
identity was kept anonymous. Samples from patients
suffering from immunological disorders were not included
in the study.

primers and two different probes, as previously described
[30]. The qRT-PCR reactions were performed in 25 µl
Ambion Ag-Path Master Mix (Life Technologies, USA)
using TaqMan Chemistry on the ABI 7500 instrument.

Viral genome extraction and real-time PCR
analysis (q-PCR and q-RT-PCR)

All patient sera were treated with receptor destroying
enzyme (RDE) (Sigma C8772, diluted 1:4), for 16 h
prior to heat inactivation (30 min, 56°C). Absorption
with erythrocytes was performed to remove non-specific
hemagglutination, in accordance with a modified WHO
protocol [31]. Serial two-fold dilutions (1:20–1:2560) of
sera in 25 μl PBS were prepared in V-shaped well plates,
and an equal volume of four hemagglutinin (HA) units of
viral antigen was added. The mixture was then incubated
at room temperature for 1 h. Fifty microliters of 0.5%
chicken erythrocytes suspended in PBS, were added to the
wells, and mixed by shaking the plates on a mechanical
vibrator. Agglutination patterns were read after 30 min
and the hemagglutination inhibition (HI) titer was defined
as the reciprocal of the last dilution of serum that fully
inhibited hemagglutination. The cut-off value selected
for a positive result was 1:40. The influenza B antigens

Hemagglutination inhibition assay

Viral genome was extracted from 500 µl of patient
Nasopharyngeal samples using the NucliSENS easyMAG
kit (BioMerieux, France), and eluted in 55 µl elution
buffer. All samples were stored at –70oC. Sentinel samples
from community patients were tested for the presence of
influenza viruses (A, B, and H1N1pdm) and respiratory
syncytial virus (RSV), by qRT-PCR as previously described
[28, 29].

Determination of influenza B lineages
To determine the influenza B lineage (Yamagta and
Victoria), all influenza B-positive samples were subjected
to a second round of qRT-PCR, performed using one set of

Figure 5: Age distribution of seropositivity against Yamagata and Victoria. Age distribution of seropositivity to Yamagata (A)
and Victoria (B) influenza B in 2014 and in 2016.
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(B/Brisbane/60/2008- Victoria and B/Massachusetts/2/2012
–Yamagata) were supplied by the WHO.

gene of influenza B viruses isolated in Japan: cocirculating
lineages in the same epidemic season. J Virol. 1990;
64:2860–2865.

Statistical analysis
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